Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 53.65M P/E - EPS this Y -2.50% Ern Qtrly Grth -
Income -65.41M Forward P/E -3.63 EPS next Y 13.20% 50D Avg Chg -5.00%
Sales - PEG -1.37 EPS past 5Y - 200D Avg Chg 66.00%
Dividend N/A Price/Book 14.83 EPS next 5Y 15.00% 52W High Chg -23.00%
Recommedations 1.50 Quick Ratio 29.08 Shares Outstanding 38.87M 52W Low Chg 464.00%
Insider Own 3.36% ROA -25.55% Shares Float 18.17M Beta -1.45
Inst Own 107.47% ROE -44.62% Shares Shorted/Prior 4.49M/3.96M Price 4.79
Gross Margin - Profit Margin - Avg. Volume 103,212 Target Price 70.25
Oper. Margin - Earnings Date Nov 5 Volume 16,248 Change -3.23%
About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Soleno Therapeutics, Inc. News
09/16/24 Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference
09/03/24 High Growth Tech Stocks To Watch In September 2024
08/28/24 Soleno Stock Up as FDA Accepts PWS Drug NDA Under Priority Review
08/28/24 Soleno wins FDA priority review for Prader-Willi therapy
08/27/24 Soleno Therapeutics, Inc. (SLNO): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
08/27/24 Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome
08/19/24 Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/15/24 Soleno Therapeutics Announces Updates to its Board of Directors
08/07/24 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07/29/24 When Can We Expect A Profit From Soleno Therapeutics, Inc. (NASDAQ:SLNO)?
07/17/24 These Stock Winners Are ‘Strong Buys’ With More Room Left to Run
06/28/24 Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
06/04/24 Soleno Therapeutics Set to Join Russell 3000® Index
05/22/24 Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
05/22/24 Soleno Therapeutics to Participate in Upcoming Investor Conferences
05/15/24 Soleno Therapeutics Stands with the Prader-Willi Syndrome Community
05/09/24 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
05/08/24 While institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the most
05/02/24 Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering Of Common Stock
05/02/24 Soleno Therapeutics Announces Proposed Public Offering of Common Stock
SLNO Chatroom

User Image Stocks4thought Posted - 17 hours ago

$CMPX Underher valued-----------two soon too-----ot $SLNO $VKTX

User Image IsabellaDC Posted - 18 hours ago

$SLNO Parabolic move is now subtly revealing.

User Image Stocks4thought Posted - 1 day ago

$IOBT ot $VOR you want more go VOR- good data- just overhang of 2nd..................................platform worth more that Dollar General---------------ot $SLNO $VKTX core holdings basis $3 and $8 was in at $3 and got prem ej!

User Image Doozio Posted - 1 day ago

$SLNO drop da 🧠 block in this 🧠⏰ cycle during 🧠⏰♾️

User Image Stocks4thought Posted - 2 days ago

$BWAY Could really smoke heavy- no float stock- https://www.youtube.com/watch?v=v2AC41dglnM ot $TALK $SLNO $VKTX

User Image IsabellaDC Posted - 2 days ago

"Best performing scan" from tradingview is where I get my moody swing list. $SMMT $SLNO $SEZL (that turned into long) $FTEL (getting interesting again) $CRBP and so on.

User Image Stocks4thought Posted - 3 days ago

$BWAY $10 soon- her time has come- ot $SLNO

User Image IsabellaDC Posted - 6 days ago

$SLNO Parabolic cycle

User Image Doozio Posted - 6 days ago

$SLNO 🧠⏰

User Image Stocks4thought Posted - 6 days ago

$BWAY $9 other LSD $SLNO $INZY $VOR $WVE

User Image Stocks4thought Posted - 6 days ago

$SLNO $60 soon milestone high cost basis sub- $3 10,000 shares. ot $INZY $VOR $WVE $VKTX

User Image Stocks4thought Posted - 6 days ago

$INZY Everyone loves $6 ot $SLNO

User Image vjtweet Posted - 1 week ago

$SLNO on watch for a breakout above 50.

User Image Stocks4thought Posted - 1 week ago

$PASG Right of Passage- Moses parts the Red Sea- Biden falls in it. ot $SLNO $VKTX $ALT $VOR

User Image Stocks4thought Posted - 1 week ago

$SGMT OT $vor $slno $vktx

User Image Doozio Posted - 1 week ago

$SLNO if no faaatch 💣 then da kitty just returned in this 🧠⏰ GME!

User Image ivanhoff Posted - 2 weeks ago

$SLNO - biotech working on a new base with a pivot around 52-53.

User Image biolevity Posted - 2 weeks ago

$MODD $SLNO $DCTH https://www.encodelp.com/coverage-universe/slno/

User Image Stocks4thought Posted - 2 weeks ago

$STOK Smoke ot $CADL $CXDX $SLNO $VKTX

User Image IsabellaDC Posted - 08/31/24

$SLNO Please do not ignore.

User Image Stocks4thought Posted - 08/30/24

$RANI Cloud bound $4.25 $SLNO $VKTX

User Image seet79 Posted - 08/29/24

$slno is this correct? We will only know by the end of the year. PDUFA) target action date of December 27, 2024.

User Image fda_tracker Posted - 08/28/24

$SLNO New PDUFA Date 2024-12-27 Soleno Therapeutics Link:https://www.globenewswire.com/en/news-release/2024/08/27/2936152/0/en/Soleno-Therapeutics-Announces-U-S-FDA-Acceptance-for-Filing-and-Priority-Review-of-NDA-for-DCCR-Diazoxide-Choline-Extended-Release-Tablets-in-Prader-Willi-Syndrome.html Calendar:http://www.fdatracker.com/fda-calendar/

User Image Stocksrunner Posted - 08/27/24

Wednesday Late-Night Market Movers: High Trading Turnover Alert $SLNO, $RMD, $BILL, $ENR, $PODD. Elevated volumes could signal brewing developments. Keep an eye on these names as market dynamics evolve.

User Image jParkz Posted - 08/27/24

$SLNO News out Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome https://marketwirenews.com/news-releases/soleno-therapeutics-announces-u-s-fda-acceptance-for-5096940039980004.html $SLNO

User Image TeresaTrades Posted - 08/27/24

Heavy options volume $TRGP $YUMC $ELAN $PVH $SLNO

User Image DonCorleone77 Posted - 08/27/24

$SLNO Soleno announces FDA acceptance for filing, priority review of NDA for DCCR Soleno Therapeutics announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application for DCCR for the treatment of Prader-Willi syndrome in individuals four years and older who have hyperphagia. The FDA granted Priority Review for the NDA and assigned a Prescription Drug User Fee Act target action date of December 27, 2024. Priority review is designated to applications for drugs that, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention or diagnosis of a serious condition. In its Priority Review Designation letter, the FDA also stated that it is currently planning to hold an advisory committee meeting to discuss the application for DCCR.

User Image Stock_Titan Posted - 08/27/24

$SLNO Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome https://www.stocktitan.net/news/SLNO/soleno-therapeutics-announces-u-s-fda-acceptance-for-filing-and-nri6k6hqxtdq.html

User Image insidemoney Posted - 08/27/24

$SLNO Soleno Therapeutics 14-Day RSI: 45.8 % from 52-Week Low: +1126.3% % from 52-Week High: -15.9% Open Interest: 31,559 % Change: +54% Put/Call Ratio: 4.2 % Change: -21.5%

User Image Kingjake26 Posted - 08/26/24

@Jrmartin2 @jacksparo if approved we could see a $SLNO move here. DMD is big time market and we would have best in class drug. $4 to $27 then moving up a lot higher. We will See :)

Analyst Ratings
Oppenheimer Outperform Aug 12, 24
Cantor Fitzgerald Overweight Jul 31, 24
Oppenheimer Outperform May 13, 24
Baird Outperform May 10, 24
Piper Sandler Overweight Feb 5, 24
Stifel Buy Jan 23, 24
Oppenheimer Outperform Jan 2, 24
Cantor Fitzgerald Overweight Sep 26, 23
Oppenheimer Outperform Sep 15, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Yen Kristen SEE REMARKS SEE REMARKS Jan 25 Sell 48.30 397 19,175 25,640 01/29/24
Hirano Patricia C SEE REMARKS SEE REMARKS Jan 25 Sell 48.30 832 40,186 43,142 01/29/24
Anish Bhatnagar CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER Jan 25 Sell 48.30 2,527 122,054 171,770 01/29/24
Hirano Patricia C See Remarks See Remarks Dec 13 Sell 37.64 6,244 235,024 19,974 12/15/23
Yen Kristen See Remarks See Remarks Dec 12 Sell 37.14 37,829 1,404,969 2,037 12/14/23
Yen Kristen See Remarks See Remarks Dec 12 Option 2.5 17,916 44,790 19,953 12/14/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Dec 11 Sell 36.09 93,408 3,371,095 24,297 12/13/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Dec 11 Sell 36.24 32,482 1,177,148 12,128 12/13/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Dec 11 Option 2.6 15,000 39,000 44,610 12/13/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Oct 20 Option 2.92 9,643 28,158 198,926 12/13/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Oct 02 Option 2.92 8,309 24,262 41,879 12/13/23
Yen Kristen See Remarks See Remarks Nov 30 Sell 28.6519 3,963 113,547 21,950 12/04/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Nov 30 Sell 28.6519 4,186 119,937 21,303 12/04/23
Hirano Patricia C See Remarks See Remarks Nov 30 Sell 28.6519 3,823 109,536 26,218 12/04/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Nov 30 Sell 28.6519 27,716 794,116 108,062 12/04/23
Yen Kristen See Remarks See Remarks Nov 28 Sell 27.58 7,650 210,987 25,913 11/30/23
Mackaness James H Chief Financial Offi.. Chief Financial Officer Nov 28 Sell 27.58 8,081 222,874 25,489 11/30/23
Hirano Patricia C See Remarks See Remarks Nov 28 Sell 27.58 7,381 203,568 30,041 11/30/23
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Nov 28 Sell 27.58 53,505 1,475,668 135,778 11/30/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Sep 26 Buy 14.76 866,789 12,793,806 3,074,542 09/28/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner May 24 Buy 5.31 85,000 451,350 2,029,455 05/26/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner May 19 Buy 5.06 80,000 404,800 1,944,455 05/23/23
SCHULER JACK W 10% Owner 10% Owner Aug 02 Sell 2.64 180,523 476,581 466,666 10/14/22
Anish Bhatnagar Chief Executive Offi.. Chief Executive Officer Jan 21 Sell 0.373 39,033 14,559 370,227 01/25/22